Australia's most trusted
source of pharma news
Friday, 31 October 2025
        
      
Posted 31 October 2025 AM
Gilead has won support for more funding for its CAR T-cell therapy, although with the caveat that they need to accept a price cut.
MSAC supported public funding of Yescarta for the treatment of patients with relapsed or refractory follicular lymphoma as third-line or later therapy, on the condition that Gilead reduce the price as part of the risk sharing agreement.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.